8-K 1 a11-7199_18k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 3, 2011

 

AMYLIN PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

0-19700

 

33-0266089

(State or Other Jurisdiction of
Incorporation)

 

(Commission File Number)

 

(I.R.S. Employer Identification No.)

 

9360 Towne Centre Drive

San Diego, California 92121

(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code:  (858) 552-2200

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CRF 240.13e-4(c))

 

 

 


 

Item 8.01.  Other Events.

 

On March 3, 2011, Amylin Pharmaceuticals, Inc. (“Amylin”) issued a press release announcing top-line results from DURATION-6, a head-to-head study designed to compare BYDUREON™ (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, to Victoza® (liraglutide (rDNA origin) injection).  A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01.  Financial Statements and Exhibits.

 

(d)           Exhibits.

 

Number

 

Description

 

 

 

99.1

 

Press release issued by Amylin on March 3, 2011.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

AMYLIN PHARMACEUTICALS, INC.

 

 

 

 

 

 

Dated:

March 3, 2011

By:

/s/ HARRY J. LEONHARDT

 

 

 

Harry J. Leonhardt

 

 

 

Vice President, Legal and Governance, and Corporate Secretary

 

3


 

EXHIBIT INDEX

 

Number

 

Description

 

 

 

99.1

 

Press release issued by Amylin on March 3, 2011.

 

4